Good morning dealmakers! Aaron Weitzman here on the Wire. Several healthcare deals have been announced this week. We’ll take a quick look at some in just a moment. But first, we’ve got a new segment of our ongoing Q&A series. Waiting game. To gain insights on the current climate for private equity deals, PE Hub and PE Hub Europe reporters have been asking a wide range of sources to share their outlooks for 2023. Today, we’re featuring PE Hub editor-in-chief MK Flynn’s interview with Andrea Auerbach, head of global private investments at Cambridge Associates. “The first six months of 2023 may be eerily similar to the last six months of 2022 in terms of deals done and pace,” Auerbach said. “There are too many factors in motion at the moment to jumpstart overall transaction volume, particularly for new platforms. That said, the public-to-private trend will continue and portfolio company add-on activity will persist.” Here’s more from the interview: What will be the most important trends affecting dealmaking in 2023? There is an expectation that 2023 will be a great year to deploy capital, provided there is price capitulation by sellers. While the public market has been on an express train to correction, private company valuations are on the local train and could take potentially another year to fully reflect the impact of broader macroeconomic factors. You can read the whole story here. Healthcare heartbeat. And now let’s explore some recent healthcare deals. Monogram Health, avalue-based specialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, received a $375 million growth capital raise to help support continued expansion. The money raised came from various investors, including CVS Health, Cigna Ventures, Humana, Memorial Hermann Health System, and SCAN, as well as from both new and existing financial investors including TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments, and Norwest Venture Partners. Separately, Q Healthcare Partners (formerly called NovaQuest Private Equity, announced it has invested in COPILOT, a “digital-first” patient-centric reimbursement hub services platform intended to support the relationship between patients, healthcare providers and pharmaceutical and device manufacturers. Speaking of healthcare, I know a lot of investors are out in San Francisco for the JPM healthcare conference. If you’re attending, I’d love to hear from you. Feel free to reach out to me at [email protected]. Environment, health and safety. Another deal announced today that caught our collective eye:New York-based Bregal Sagemount made a strategic growth investment in Enhesa, a provider of regulatory and sustainability intelligence, in a deal covered by PE Hub Europe’s Nina Lindholm. As part of the transaction, Sagemount will acquire ICG’s minority stake in Enhesa, with existing investor CGE Partners retaining its majority stake in the company. Enhesa has its global headquarters in Brussels and its US headquarters in Arlington, Virginia. You can read the whole story here. That is a wrap for today. Chris Witkowsky in on deck for tomorrow, MK Flynn will be with you on Thursday, and I will be back on Friday as per usual. Until then… Cheers, Aaron Read thefull wire commentaryon PE Hub … |